Beijing Foyou Pharma (601089.SH) has obtained the approval notice for the listing application of the raw material kelevoron.
Fukuyuan Pharmaceuticals (601089.SH) announced that the company recently received approval and issuance of the National Medical Products Administration...
Beijing Foyou Pharma (601089.SH) announced that the company has recently received the approval issued by the National Medical Products Administration for the raw material drug Klietolol, "Chemical Raw Material Drug Market Application Approval Notice". Klietolol is used for the topical treatment of mild to moderate atopic dermatitis patients aged 2 and above.
This approval will further enrich the company's product line and promote the company's continuous, stable, and healthy development.
Related Articles
PW MEDTECH (01358) spent HKD 640,900 to repurchase 436,000 shares on October 24th.
Appointment of Mr. Wen Xiaojian as Executive Director and Acting Chief Executive Officer of ZHAOBANGJI LIFE (01660)
On October 24th, MENGNIU DAIRY (02319) spent 5.7447 million Hong Kong dollars to repurchase 400,000 shares.
PW MEDTECH (01358) spent HKD 640,900 to repurchase 436,000 shares on October 24th.
Appointment of Mr. Wen Xiaojian as Executive Director and Acting Chief Executive Officer of ZHAOBANGJI LIFE (01660)
On October 24th, MENGNIU DAIRY (02319) spent 5.7447 million Hong Kong dollars to repurchase 400,000 shares.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
